Ilyas Sahin is an Oncology physician affiliated with Harvard University. OpenAlex indexes 135 publications with 2,419 citations (h-index 23).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Boston, MA 021142621
Telephone
617-726-2000Provider last certified this registry record 22 Jan 2026.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
- Novartis Pharmaceuticals CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
50%Phenothiazine22.9%Prochlorperazine Maleate100%Part D≥32 patientsOpioid Agonist21.2%Oxycodone Hcl65%Morphine Sulfate Er35%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
18.8%Serotonin-3 Receptor Antagonist7.9%Ondansetron Odt100%Part D<11 patientsProton pump inhibitor5.8%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
12.1%Kinase inhibitor12.1%Lenvima100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma
2024 - Immune checkpoint inhibitors in the posttransplant landscape of HCC: A systematic literature review
Liver Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Felipe Fregni, MD, MPH
Harvard University
Joseph Antin, MD
Harvard University
Sarah Fortune, MD
Harvard University
Elizabeth Buchbinder, MD
Harvard University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”